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Um método simples e rápido por eletroforese capilar foi desenvolvido e validado para 
a quantificação do inibidor não nucleosídeo da transcritase reversa (NNRTI) nevirapina, 
em medicamentos. A análise foi otimizada utilizando tampão fosfato de sódio 10 mmol L-1, 
pH 2,5, voltagem aplicada de +25 kV, injeção hidrodinâmica a 0,5 psi por 5 s e detecção UV 
em 200 nm. Diazepam (50,0 µg mL-1) foi usado como padrão interno. Sob estas condições, 
nevirapina foi analisada em aproximadamente menos de 2,5 min. A curva analítica apresentou 
um coeficiente de correlação de 0,9994. Os limites de detecção e quantificação foram 
1,4 µg mL-1 e 4,3 µg mL-1, respectivamente. Precisões intra e inter-dia expressas como desvio 
padrão relativo foram 1,4% e 1,3%, respectivamente e a recuperação média foi de 100,81%. 
O fármaco foi submetido a testes de hidrólises (ácida, básica e neutra) e a estresse oxidativo. 
Não foi observada interferência por parte dos produtos de degradação, nem dos excipients na 
análise da nevirapina. Este método mostrou ser rápido, simples, preciso, exato e econômico 
para a determinação de nevirapina em produtos farmacêuticos e é apropriado para o controle 
de qualidade em análise de rotina uma vez que a eletroforese capilar oferece benefícios em 
termos de desenvolvimento rápido dos métodos e custos muito reduzidos de operação.
A simple and fast capillary zone electrophoresis (CZE) method has been developed and 
validated for quantification of a non-nucleoside reverse transcriptase inhibitor (NNRTI) 
nevirapine, in pharmaceuticals. The analysis was optimized using 10 mmol L-1 sodium 
phosphate buffer pH 2.5, +25 kV applied voltage, hydrodynamic injection 0.5 psi for 5 s and 
direct UV detection at 200 nm. Diazepam (50.0 µg mL-1) was used as internal standard. Under 
these conditions, nevirapine was analyzed in approximately less than 2.5 min. The analytical 
curve presented a coefficient of correlation of 0.9994. Limits of detection and quantification 
were 1.4 µg mL-1 and 4.3 µg mL-1, respectively. Intra- and inter-day precision expressed as 
relative standard deviations were 1.4% and 1.3%, respectively and the mean recovery was 
100.81%. The active pharmaceutical ingredient was subjected to hydrolysis (acid, basic and 
neutral) and oxidative stress conditions. No interference of degradation products and tablet 
excipients were observed. This method showed to be rapid, simple, precise, accurate and 
economical for determination of nevirapine in pharmaceuticals and it is suitable for routine 
quality control analysis since CE offers benefits in terms of quicker method development and 
significantly reduced operating costs.
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Introduction
Nevirapine (11-cyclopropyl-4-methyl-5,11-dihydro-
6H-dipyrido[3,2-b:2’,3’-e][1,4]diazepin-6-one)1,2 is a 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 
that stops HIV from multiplying by preventing the reverse 
transcriptase enzyme from working. This drug is usually 
included in the generic fixed-dose combinations and 
has shown efficacy in advanced HIV disease.3 Several 
analytical methods have been developed for analyzing 
nevirapine and other antiretroviral drugs including 
derivative UV spectrophotometry4 and high performance 
thin layer chromatography (HPTLC).5 High performance 
liquid chromatography (HPLC) has been widely used for 
determination of antiretrovirals in both biological fluids and 
pharmaceutical formulations,6-11 hyphenated HPLC-MS12-17 
systems have also been introduced for the determination of 
antiretrovirals in plasma. Many of these methods require 
the use of expensive and hazardous chemicals which 
make the process complex, time consuming and costly. 
Capillary electrophoresis has become an active research 
and development area of considerable interest in analytical 
chemistry and has been widely adopted for the analysis 
of drugs and pharmaceuticals18 due to its simplicity, wide 
application, small sample volume requirement, short 
analysis time, high resolution and low running cost with 
eco-friendly solvents as compared to HPLC.
Several CE methods were also available in the 
recent literature for the determination and separation of 
antiretroviral drugs in serum samples using solid phase 
extraction procedures.19-22 Hyphenated CE-MS systems 
were also used.23 A few CE methods were reported for 
the determination and validation of antiretrovirals drugs 
in bulk drugs and pharmaceutical formulations.24,25 Sekar 
and Azhaguvel,25 separated and determined lamivudine and 
stavudine with the nevirapine (NNRTI) in pharmaceutical 
formulations by micellar electrokinetic capillary 
chromatographic (MEKC) method, all antiretroviral 
drugs were separated within 14 min using 10 mmol L-1 
sodium tetraborate (pH 9.8), 100 mmol L-1 SDS and 15% 
2-propanol as an organic modifier. The development of a 
simple CZE method when compared with MEKC method 
can supply a very useful alternative for routine analysis of 
pharmaceutical formulations.
Thus, as part of our ongoing anti-HIV research and 
considering that nevirapine is currently part of the AIDS 
treatment, there is a need to develop specific methodologies 
for its quality control. The aim of this study was to develop 
and validate a rapid, simple, inexpensive and environmental 
friendly capillary zone electrophoresis method, which is 
much faster than the existing MEKC or even CZE methods, 
for the determination of nevirapine in drug substance and 
formulated products suitable for routine quality control 
analysis and stability tests.
Experimental
Reagents and chemicals
All the reagents used in the method development 
and validation were of analytical grade, the solvents of 
chromatographic purity and the water was purified by 
deionization (Milli-Q, Millipore, Bedford, MA, USA). The 
electrolyte buffer phosphate at 10 mmol L-1 concentration 
and pH 2.52 was prepared by dissolution of equimolar 
amounts of sodium dihydrogenphosphate dehydrate 
(Merck, São Paulo, Brazil) and o-phosphoric acid (Sigma, 
Milwaukee, WI, USA). Nevirapine (Figure 1A) and 
diazepam (Figure 1B) standards were kindly donated by 
Farmanguinhos (Rio de Janeiro, Brazil) and used without 
further purification. Commercial samples of nevirapine 
tablets containing 200.0 mg of nevirapine were obtained 
from three local laboratories (São Paulo, Brazil) named 
laboratory A, B and C. 
Equipment and capillary conditioning
The experiments were performed using two CE systems: 
model P/ACE 5510 (Beckman Coulter Instruments, 
Fullerton, CA, USA), equipped with a variable UV-Vis, 
software for data acquisition and treatment (Beckman P/
ACE System Gold Software) and model HP3DCE (Agilent 
Technologies, Palo Alto, CA, USA), equipped with a diode 
array detector, software for data acquisition and treatment 
(HP ChemStation, rev A.08.03). Samples were introduced 
onto the capillary via hydrodynamic injection (0.5 psi for 
5 s, Beckman instrument, 1 psi = 6894.76 Pa; 50 mBar for 
5 s, Agilent instrument, 1 mBar = 100 Pa). The instruments 
were operated under positive polarity, with a constant 
voltage of +25 kV. Detection wavelength was set at 200 nm 
and the capillary temperature was 25 ºC.
Figure 1. Chemical structures of nevirapine (A) and diazepam (B).
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For capillary conditionating an uncoated fused-silica 
capillaries (Polymicro Technologies, Phoenix, AZ, USA) 
with an inner diameter of 75 µm and total length of 27.0 cm 
(19.4 cm to the detector) for Beckman instrument and 
31.5 cm (23.0 cm to the detector) for Agilent instrument 
were used. New capillaries were conditioned by flushes 
with 1 mol L-1 NaOH (30 min), followed by deionized 
water (30 min) and electrolyte (10 min). At the beginning 
of the day, the capillary was conditioned with 1 mol L-1 of 
NaOH for 5 min, followed by deionized water for 5 min and 
electrolyte buffer for 10 min. In between runs, the capillary 
was rinsed with the electrolyte solution for 1 min. At the 
end of the day, a final 5 min wash with 1 mol L-1 NaOH 
and water was performed.
Preparation of standard solutions
Separate standard stock solutions of nevirapine 
(200.0 µg mL-1) and diazepam (500.0 µg mL-1), used as 
internal standard (IS), were prepared in acetonitrile and 
methanol, respectively. Working standard solutions were 
prepared fresh daily by diluting appropriately the stock 
solutions with deionized water.
Sample preparation 
Twenty tablets of each sample (laboratories A, B and C) 
were finely powdered. Amounts corresponding to 20.0 mg 
of nevirapine of each sample were weighed, transferred 
into separate 100 mL volumetric amber flasks; 50 mL of 
acetonitrile was added to each flask for dissolution. The 
volume was completed with deionized water. The solutions 
were sonicated for 10 min and filtered using a 0.45 µm filter 
(Millipore), rejecting the first 5 mL. Aliquots of 5 mL of 
these solutions and 1.0 mL of standard stock solution of 
diazepam (500.0 µg mL-1) were transferred into 10 mL 
volumetric amber flasks and volumes were completed with 
deionized water. Final concentrations were 100.0 µg mL-1 
and 50.0 µg mL-1 for nevirapine and diazepam, respectively. 
A standard solution was prepared at the same concentration 
of the sample, following the procedure described above. 
The samples and the standards solutions were sonicated 
for 10 min prior to introduction onto the capillary column.
Stress testing
For stress degradation studies the drug substance, 
nevirapine, was subjected to neutral, acid and alkaline 
hydrolysis and chemical oxidation. Individually 10.0 mg mL-1 
of the drug were diluted with 5 mL of water, 1 mol L-1 HCl 
and 1 mol L-1 NaOH solutions in 10 mL volumetric flasks, 
the volumes were completed with acetonitrile. To analyze 
chemical oxidation, 10.0 mg mL-1 of the drug was diluted 
with 5 mL 3% H2O2 solution in a 10 mL volumetric flask. 
These mixtures were heated at 80 ºC for 2 h. After completion 
of the degradation processes, the acid and alkaline solutions 
were neutralized. After stressing time adequate dilutions 
were made from each solution. The final concentration of 
nevirapine was 100.0 µg mL-1. 
Method validation
The proposed CZE method was validated based on 
the recommendations of the International Conference 
on Harmonization26 and United States Pharmacopeia2 
guidelines.
Linearity 
Aliquots of 4.0, 4.5, 5.0, 5.5, and 6.0 mL from the 
standard stock solution of nevirapine (200.0 µg mL-1) and 
aliquots of 1.0 mL from standard stock solution of diazepam 
(500.0 µg mL-1) were transferred into separate 10 mL 
volumetric amber flasks. The volumes were completed 
with deionized water. Concentration range from 80.0 to 
120.0 µg mL-1 of nevirapine, and 50.0 µg mL-1 of diazepam 
were obtained. The solutions were sonicated for 10 min, and 
filtered using a 0.45 µm filter (Millipore) prior injection.
Precision
The repeatability (intra-day precision) was determined 
preparing samples solutions of nevirapine at three 
concentration levels (80.0, 100.0 and 120.0 µg mL-1) of 
the analytical curve with a constant amount of diazepam 
(50.0 µg mL-1) (IS). Three determinations of each 
concentration level were performed.
The intermediate precision (inter-day precision) was 
evaluated as described in repeatability, but it was performed 
in three different days. Precision was expressed by the 
relative standard deviation (RSD%) for peak area ratio 
(PAR) of nevirapine/IS.
Accuracy (recovery test)
To determine the accuracy of the CZE method, recovery 
experiments were performed according to procedures 
endorsed by AOAC International.27 Nevirapine standard 
stock solution was added to commercial sample solutions 
and analyzed by the proposed method, according to the 
procedure depicted in Table 1.
Robustness
To determine the robustness of the method statistical 
comparison of assay results was performed by two different 
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CE instruments. Significance tests were performed in the 
results to verify whether there is a statistically significant 
difference. Moreover, the effects of the applied voltage 
(22-28 kV) and capillary temperature (22-28 ºC) were 
deliberately modified. Standard solutions containing 
100.0 µg mL-1 of nevirapine and 50.0 µg mL-1 of diazepam 
(IS) were prepared and injected in triplicate. Relative 
standard deviations (RSD %) for peak area ratio (PAR) of 
nevirapine/IS were obtained.
Results and Discussion
Prior to method development, a few structural 
characteristics of the compound structure were taken into 
account. The basic character of nevirapine (Figure 1A) 
makes it a suitable molecule for CE analysis. The overall 
charge of the molecule and consequently its mobility 
can be modified by controlling the electrolyte buffer 
pH. At low pH, the amine groups are readily protonated 
and the molecule bears a positive charge. At this low pH 
condition, only the electrophoretic mobility contributes 
for the net transport of the analyte towards the detector, 
since a negligible electroosmotic flow is observed. Thus, 
a good choice for the electrolyte is a phosphate buffer, 
which presents adequate buffering capacity around pH 
2.5. An internal standard (diazepam, Figure 1B) was 
selected. Internal standards are often used to minimize 
injection volume fluctuations, dilution errors and errors 
during sample treatment. The proper choice of an internal 
standard can substantially improve precision of peak area 
determinations. The choice of detection wavelength was 
based on the inspection of the UV spectra of nevirapine and 
diazepam in the optimal electrolyte (not shown). In order 
to assure the method maximum sensitivity and accuracy, 
200 nm was selected. Figure 2 illustrates the separation of 
diazepam and nevirapine standards under selected optimal 
conditions, confirming that diazepam performs well as 
internal standard. Migration times were approximately 2.0 
and 2.6 min, respectively. 
Sekar and Azhaguvel,25 using micellar electrokinetic 
chromatography (MEKC) method separated nevirapine 
from lamivudine and stavudine (tablets) in approximately 
12 min. The migration time of nevirapine is approximately 
five times higher when compared with the proposed CZE 
method. Furthermore, the CZE method did not generate 
hazardous organic solvents in contrast to MEKC method 
above described which uses 2-propanol.
In the HPLC methods described by Sarkar9 and Kapoor10 
the authors identified nevirapine in about 5 and 14.5 min, 
respectively in pharmaceutical tablet form. Rebiere11 
separated nevirapine from the others antiretrovirals drugs 
in approximately 2.7 min but nevirapine was not well 
separated from fosamprenavir drug.
The applicability of proposed method to commercial 
sample tablets containing nevirapine is demonstrated by 
Figure 3B.
Before a method is routinely used, it must be validated. 
The validation process provides that the method is 
acceptable for its purpose. In the present work the CZE 
method was validated by determining its performance 
characteristics regarding specificity, linearity, limits of 
detection and quantification, precision, accuracy, robustness 
and system suitability.2,26 All validation parameters 
were determined using Beckman instrument except for 
specificity (Agilent instrument) and robustness, which 
was assessed during sample analyses in both Beckman and 
Agilent instruments.
System suitability tests are used to verify that the 
resolution and reproducibility of the chromatographic 
system are adequate for the analysis to be done.2 According 
Table 1. Procedure for the recovery test (standard solution of nevirapine 
added to commercial sample solution)
Nevirapine 
standard solution 
(200.0 µg mL-1)
Commercial 
samplea 
(200.0 µg mL-1)
Final concentration / 
(µg mL-1)
Aliquots / mLb Aliquots / mLb Nevirapine Internal Standard
2 2 80 50
2.5 2.5 100 50
3 3 120 50
aProcedure was performed on commercial samples A, B and C; bto 10 mL 
volumetric amber flasks.
Figure 2. Electropherogram of nevirapine (peak 1; 100.0 µg mL-1) and 
diazepam (peak 2; 50.0 µg mL-1) standard drugs. Conditions: silica-fused 
capillary with 75 µm i.d. and a total length of 27 cm (19.4 cm to the 
detector), electrolyte constituted of 10 mmol mL-1 phosphate buffer at 
pH 2.5, hydrodynamic injection 0.5 psi for 5 s, UV detection at 200 nm, 
applied voltage +25 kV. 
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to the FDA28 theoretical plate number must be higher 
than 2000, tailing factor ≤ 2, and resolution higher 
than 2. Table 2 shows the results obtained for nevirapine 
(100.0 µg mL-1 and diazepam (50.0 µg mL-1) standard 
solutions. All parameters are in accordance with FDA 
recommendations.
Since sample placebo was not available, the method 
specificity was attested by inspection of the spectral purity 
of the nevirapine peak in the sample electropherogram 
(Agilent instrument, not shown). A purity index superior 
to 98.8% was obtained, confirming the method specificity 
for nevirapine. Furthermore, was demonstrated non-
interference between nevirapine and excipients from the 
sample (Figure 3B). 
To establish the method linearity, diluted fortified 
standard solutions were injected in triplicate and average 
peak area ratios (nevirapine/diazepam) were plotted against 
the corresponding nevirapine concentrations. Linearity 
was assessed by least-squares regression analysis.29 
Coefficients of correlation (0.99 or greater) and intercept 
close to the origin should be obtained.30 As shown by the 
statistical data organized in Table 3, the method exhibited 
excellent linearity (r > 0.999) over the concentration range 
80.0-120.0 µg mL-1. Limits of detection and quantification 
were 1.4 µg mL-1 and 4.3 µg mL-1, respectively. The 
criterion used to determine the limit of detection (LOD) and 
quantification (LOQ) was based on the residual standard 
deviation (SE) of the regression line of the analytical curve 
and its slope (S) (Table 3), according to LOD = 3.3 SE/S 
and LOQ = 10 SE/S.31 
The intra- and inter-day precisions of the proposed 
analytical method were determined at concentrations 
in the low, middle and high linearity range with the 
constant amount of IS. The RSD % values for the peak 
area ratios are given in Table 4. Averages values of 1.4% 
and 1.3% RSD for intra- and inter-day precision were 
obtained indicating a good agreement among individual 
test results. The criterion for precision demands a RSD 
smaller than 2%.18
The method accuracy was evaluated as the percentage 
recovery of a known amount of standard added to samples 
as endorsed by ICH26 and AOAC International27 protocols. 
Table 5 shows that recoveries ranged from 99.64 to 
102.46% for three concentration level. Mean recoveries 
should be within 100 ± 2% at each concentration level over 
the range 80-120% of the target concentration.1
Figure 3. Electropherograms of: A) nevirapine (peak 1; 100.0 µg mL-1) 
and diazepam (peak 2; 50.0 µg mL-1) standard solutions. B) Typical 
pharmaceutical sample (tablet from laboratory A). Conditions: capillary 
of silica-fused with 75 µm i.d. and a total length of 27 cm (19.4 cm to 
the detector), electrolyte: 10 mmol mL-1 phosphate buffer at pH = 2.5, 
injection: 0.5 psi for 5 s, detection at 200 nm, voltage: +25 kV. 
Table 2. System suitability testing for CZE method
Parameters
CZE
Nevirapine Diazepam
Theoretical plates (N, plates/m) 1.27 × 104 2.2 × 104
Asymmetry (As) 1.5 1.0
Selectivity (a) (IS-nevirapine) 1.3
Resolution (Rs) (IS-nevirapine) 3.25
IS: internal standard (diazepam).
Table 3. Linearity, limit of detection and limit of quantification determined 
for the proposed CZE method
Parameter Statistical data
Concentration rangea / (µg mL-1) 80-120
Intercept 0.3542
Slope (S) 0.0207
Coefficient of determination (r) 0.9994
Residual SD of the regression line 0.00886
Limit of Detection / (µg mL-1) 1.4
Limit of Quantification / (µg mL-1) 4.3
aFive data points, three replicate injections at each concentration level.
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Samples of nevirapine tablets from three different 
laboratories were assayed against a reference standard 
solution of nevirapine to establish the assay. Both solutions 
were prepared at 100.0 mg mL-1 of nevirapine. The results in 
Table 6 demonstrated that the proposed method is suitable 
for determination of nevirapine in tablets within tolerance 
limits (90-110% label claim).
The robustness of the proposed method was evaluated 
by statistical comparison of assay results generated by two 
different CE instruments (Table 6). Significance tests were 
performed in the results (Table 7). As observed, calculated 
F values are smaller than the critical F value, attesting that 
there is no statistical difference in the assay results, at a 
confidence level of P = 95%.32 Furthermore, no significant 
changes were observed in the instrumental responses when 
the analytical parameters were deliberately modified. When 
the voltage was changed from 22 kV to 28 kV, the values 
of RSD% were 1.52% and 1.53%, respectively for PAR 
of nevirapine/IS and when the temperature was changed 
from 22 ºC to 28 ºC, the RSDs% were 1.07% and 1.17%, 
respectively for PAR of nevirapine/IS. These results 
obtained were similar to those of the initial conditions 
(25 kV and 25 ºC). Thus, the proposed method can be 
considered robust and reliable. 
CZE studies of drug nevirapine obtained on stress 
testing suggested the following degradation behavior. 
Degradation was not observed when nevirapine was 
subjected to neutral hydrolysis (water at 80 ºC for 2 h) 
(Figure 4B). Significant degradation was observed when 
the drug was subjected to alkaline hydrolysis (1 mol L-1 
NaOH at 80 ºC for 2 h), leading to the formation 
of unknown degradation products in approximately 
1.2 (major peak) and 4.6 min (Figure 4C). The same 
was observed under oxidative conditions (3% H2O2 
at 80 ºC for 2 h) leading to the formation of unknown 
degradation peaks in approximately 1.4, 1.6, and 
3.7 min, the major product was seen at around 1.6 min 
(Figure 4E). Under acidic conditions (1 mol L-1 HCl at 
80 ºC for 2 h) nevirapine was almost completely degraded 
(Figure 4D). The proposed CZE method was appropriate 
for quantitative determination of nevirapine in the 
presence of its degradation products.
Table 4. Intra and inter-day precision of the proposed CZE method for 
nevirapine quantitative determination
Precision
Sample concentration / (µg mL-1)
80.0 100.0 120.0
Intra-day / (% RSD for PAR)a 1.2 1.4 1.7
Average / (%RSD) 1.4
Inter-day / (% RSD for PAR)a
Day 1 1.7 1.1 1.7
Day 2 1.0 1.7 1.1
Day3 1.1 1.7 1.0
Average / (%RSD)b 1.3
PAR: peak area ratio (nevirapine/internal standard). aThree determinations 
at each concentration level. bAverage of relative standard deviation (27 
determination).
Table 5. Recovery of a standard solution of nevirapine added to samples 
and determined using the proposed CZE method
Standard added to 
commercial samples / 
(µg mL-1)
Standard found / 
(µg mL-1)
Samples
Recoverya / 
(%)
Samples
A B C A B C
40.0 39.87 40.13 40.54 99.68 100.33 101.35
50.0 51.23 50.35 49.82 102.46 100.70 99.64
60.0 59.95 61.28 60.65 99.92 102.13 101.08
aAverage of three determinations. A, B and C: pharmaceutical laboratories.
Table 6. Assay results for sample tablets of nevirapine
Results P/ACE 5100
Aa Ba Ca
Amount declared / 
(mg per tablet)
200.0 200.0 200.0
Amount found / 
(mg per tablet)
198.65 ± 0.96 195.60 ± 1.44 198.23 ± 0.84
Purity / (%) 99.32 97.80 99.11
RSD / (%) 0.48 0.74 99.11
HP3DCE
Amount declared / 
(mg per tablet)
200.0 200.0 200.0
Amount found / 
(mg per tablet)
198.88 ± 1.33 196.33 ± 1.63 198.07 ± 1.48
Purity / (%) 99.44 98.16 99.03
RSD / (%) 0.67 0.83 0.75
aAverage of three determinations. A, B and C: pharmaceutical laboratories.
Table 7. Results obtained in the comparison of the precision of nevirapine 
determination, using the two CE equipmentsa
Samples Comparison between HP3DCE and P/ACE MDQ 
Precision, calculated F-valueb
A 1.39
B 1.13
C 1.76
A, B and C: Pharmaceutical laboratories. aHP3DCE: capillary 
electrophoresis system from Agilent Technologies and P/ACE MDQ: 
capillary electrophoresis system from Beckman Coulter Inc. bTabulated 
Snedecor F-value with P = 95%, F2,2 = 1929.
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Conclusions
A fast, simple and reliable CZE method for the 
determination of nevirapine in tablets has been developed 
and validated. This electrophoretic assay fulfilled all the 
requirements to be identified as a reliable and feasible 
method, including linearity, accuracy, robustness and 
precision data. It is a highly specific and precise analytical 
procedure. Therefore, this method performance makes it 
suitable for implementation in pharmaceutical laboratories 
for routine analysis of nevirapine formulations and raw 
materials and it can be used as a stability-indicating method.
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